Glycadia, Inc. aka Glycadia Pharmaceuticals
Glycadia is developing drugs to prevent and treat the kidney, eye, nerve and cardiovascular complications that result from diabetes
Glycadia's drugs target cell-signaling pathways that cause kidney, eye, nerve and cardiovascular complications of diabetes. These drugs are effective independent of glucose control. Currently there are no drugs that effectively halt the progression of complications of diabetes, which remain a significant unmet medical need as well as a major market opportunity. In the U.S. there are 5 million diabetics who have symptoms leading to complications.